Since time immemorial, phages—the viral parasites of bacteria—have been protecting
Earth's biosphere against bacterial overgrowth. Today, phages could help address the …

Background Across European countries, differences exist in biosimilar policies, leading to
variations in uptake of biosimilars and divergences in savings all over Europe. Objectives …

To date, no consensus exists among stakeholders about switching patients between
reference biological products (RPs) and biosimilars, which may have been curbing the …

The present opinion is the result of discussions on the future of phage therapy (personalized
or large-scale uniform therapy?) during the first International Congress on Viruses of …

The worldwide antibiotic crisis has led to a renewed interest in phage therapy. Since time
immemorial phages control bacterial populations on Earth. Potent lytic phages against …

Objectives: The aim of this study is to conduct an analysis on the regulation and application
of managed entry agreements (MEA) for oncology drugs across different European …

Drug shortages are a complex and global phenomenon. When a drug cannot be delivered
at the moment of patient demand, every stakeholder in the health care system is affected …

Phage therapy is increasingly put forward as a “new” potential tool in the fight against
antibiotic resistant infections. During the “Centennial Celebration of Bacteriophage …

Background Drug shortages are a global problem. While extensively studied in the United
States, numbers about drug shortages in European countries are scarce. This study aims to …

Background: Biopharmaceutical medicines represent a growing share of the global
pharmaceutical market, and with many of these biopharmaceutical products facing loss of …